Company news
Halozyme Therapeutics, Inc. news in 2023
Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis
November 15, 2023
Halozyme reports third quarter 2023 financial and operating results
November 5, 2023
Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease
November 5, 2023
Halozyme To Report Third Quarter 2023 Financial and Operating Results
October 29, 2023
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
October 18, 2023
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
October 15, 2023
Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery
October 15, 2023
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
August 28, 2023
Halozyme reports second quarter 2023 financial and operating results
August 7, 2023
Halozyme To Report Second Quarter 2023 Financial and Operating Results
July 24, 2023
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 16, 2023
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
July 12, 2023
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
June 19, 2023
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Halozyme reports first quarter 2023 financial and operating results
May 8, 2023
Halozyme To Report First Quarter 2023 Financial and Operating Results
April 24, 2023
Halozyme reports fourth quarter and full year 2022 financial and operating results
February 20, 2023
Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results
February 6, 2023
Halozyme Appoints Barbara Duncan to its Board of Directors
February 5, 2023
Halozyme Therapeutics, Inc. announces redemption of 1.25% convertible senior notes due 2024
January 10, 2023
Halozyme Provides 2023 Financial Guidance and Outlook
January 9, 2023
Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Calls in 2023
- Halozyme Therapeutics (NASDAQ:HALO) Q3 2023 Earnings Call
Nov 6, 2023
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q2 2023 Earnings Call
Aug 8, 2023
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q1 2023 Earnings Call
May 9, 2023
Transcript - Halozyme Therapeutics (NASDAQ:HALO) Q4 2022 Earnings Call
Feb 21, 2023
Transcript
Decks in 2023
- Q3 2023 Earnings Presentation
Earnings · 19 slides · Nov 6, 2023
- Q2 2023 Earnings Presentation
Earnings · 17 slides · Aug 8, 2023
- Q1 2023 Earnings Presentation
Earnings · 17 slides · May 9, 2023
- Q4 2022 Earnings Presentation
Earnings · 18 slides · Feb 21, 2023
- 41st Annual J.P. Morgan Healthcare Conference (January 2023)
Conference · 34 slides · Jan 10, 2023